Last Friday, researchers in Atlanta injected millions of embryonic stem cells into a patient with a damaged spine, in the first clinical trial of embryonic stem cells in a human being. Phase I is for safety, but they're looking for therapeutic consequences as well. Some critics say it's premature, while others contend it's immoral. Rob Stein is national science reporter at the Washington Post.
KCRW
